Hereditary Angioedema Market: By Product (Kalbitor, Ruconest, Icatibant, Firazyre, Berinert, Orladeyo, Cinryze, Haegarda and Takhzyro), By Drug Class (C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor and Others) By Route of Administration (Intravenous, Subcutaneous and Oral) and Geography (North America, Europe, Asia Pacific, Latin America and MEA)

Purchase Option

$ 4400
$ 6600
$ 8900

Hereditary Angioedema Market was valued at USD 1,056.1 million in 2019 and grown at 37.4% CAGR over the historic years (2019-2022) to reach USD 2,737.3 Million in 2022. Hereditary Angioedema (HAE) is a hereditary disease. There is a 50% probability that a parent with HAE will pass it on to their offspring. As a result of a spontaneous gene mutation, HAE can also develop in people with no family history. HAE is managed by acute attack management, short-term prophylaxis, and long-term prophylaxis. The Kalbitor, Ruconest, Icatibant, Firazyr and Berinert are using for acute attack management. The Orladeyo, Cinryze, Haegarda, and Takhzyro drugs are using for short-term and long term prophylaxis treatment. The diversity of HAE's phenotype makes diagnosis challenging. Initial misdiagnoses happen frequently. For instance, HAE-related edoema can be mistaken for an allergic reaction. It is possible to misinterpret gastrointestinal symptoms for the gastrointestinal disease alone. Due to its rarity and significant symptom overlap with other conditions, HAE is rarely detected early, usually disregarded, and misdiagnosed. The right diagnosis typically takes a patient more than 10 years after the onset of symptoms. Even though the illness is uncommon, it is dangerous.

STAR 0125 for Hereditary Angioedema Therapeutics and Market Value (USD Million), 2027 -2030 in USA

Hereditary Angioedema Market

KalVista (Sebetralstat – On Demand & KVD-824 - Prophylaxis) for Hereditary Angioedema Therapeutics and Market Value (USD Million), 2024 -2029 in USA

 

Hereditary Angioedema Market Key Developments:
  • In February 2023, BioCryst Pharmaceuticals, Inc. unveiled major statistics from the APeX-S and APeX-2 clinical trials which assessed oral, once-daily ORLADEYO® (berotralstat) for the preventative treatment of hereditary angioedema (HAE) exhibiting sustained declines in attack rates and a boost in quality of life (QoL) among patients living with HAE, showcasing its profile as a well-tolerated, effective and convenient prophylactic HAE therapeutic option.
  • In September 2022, CSL Behring has received manufacturing and marketing approval from MHLW (Japan) for Berinert® S.C. Injection 2000, for the prevention of acute HAE attacks. Berinert® S.C. Injection 2000 is administered twice-weekly as subcutaneously and it can be self-administered at home.
  • In August 2022, CSL Behring’s Garadacimab (CSL312), the company's experimental first-in-class monoclonal antibody blocking Factor XIIa that is being developed as a long-term preventative therapy for individuals with hereditary angioedema, has received good top-line Phase 3 findings (HAE). The trial accomplished its primary and secondary effectiveness goals while also demonstrating good safety and acceptability. CSL intends to begin submitting with global health authorities for complete clearance by the conclusion of the current fiscal year.

Hereditary Angioedema Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

37.4%

Largest Market

Asia Pacific

Fastest Growing Market

North America
Hereditary Angioedema Market Pipeline Analysis

Around 14 drug molecules are in various clinical developmental stages, the majority of the molecules are in phase-I & II clinical stages. And few drug molecules such as KVD-900, CSL 312; Factor XIIa antagonist monoclonal antibody, Donidalorsen, are in Phase III clinical developmental stages.



Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Hereditary Angioedema Market Segmentation

By Product Type
  • Kalbitor
  • Ruconest
  • Icatibant
  • Firazyre
  • Berinert
  • Orladeyo
  • Cinryze
  • Haegarda
  • Takhzyro
  • Others
By Drug Class
  • C1-esterase inhibitor
  • Bradykinin B2 receptor antagonist
  • Kallikrein inhibitor
  • Others
By Route of Administration
  • Intravenous
  • Subcutaneous
  • Oral
  • Others
By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

The hereditary angioedema market size was valued at USD 2,737.3 Million in 2022

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

The hereditary angioedema market key players are CSL Behring (Garadacimab) Takeda Pharming Biocryst Pharmaceutics (BCX-4161) Pharvaris (PHA 121) Ionis Pharmaceuticals (Donidalorsen)

1.Executive Summary
2.Global Hereditary Angioedema Market Introduction 
2.1.Global Hereditary Angioedema Market  - Taxonomy
2.2.Global Hereditary Angioedema Market  - Definitions
2.2.1. By Product Type 
2.2.2. By Drug Class
2.2.3. By Route of Administration
2.2.4. By Region
3.Global Hereditary Angioedema Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Hereditary Angioedema Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Hereditary Angioedema Market  By Product Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Kalbitor
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Ruconest
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Icatibant
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Firazyre
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Berinert
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Orladeyo
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. Cinryze
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.7.3. Market Opportunity Analysis 
5.8. Haegarda
5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.8.3. Market Opportunity Analysis 
5.9. Takhzyro
5.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.9.3. Market Opportunity Analysis 
5.10. Others
5.10.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.10.3. Market Opportunity Analysis 
6.Global Hereditary Angioedema Market  By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. C1-esterase inhibitor
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Bradykinin B2 receptor antagonist
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Kallikrein inhibitor
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Others
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.Global Hereditary Angioedema Market  By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Intravenous
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Subcutaneous
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Oral
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Others
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Hereditary Angioedema Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Hereditary Angioedema Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Product Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Kalbitor
9.1.2.Ruconest
9.1.3.Icatibant
9.1.4.Firazyre
9.1.5.Berinert
9.1.6.Orladeyo
9.1.7.Cinryze
9.1.8.Haegarda
9.1.9.Takhzyro
9.1.10.Others
9.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.C1-esterase inhibitor
9.2.2.Bradykinin B2 receptor antagonist
9.2.3.Kallikrein inhibitor
9.2.4.Others
9.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Intravenous
9.3.2.Subcutaneous
9.3.3.Oral
9.3.4.Others
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Hereditary Angioedema Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Kalbitor
10.1.2.Ruconest
10.1.3.Icatibant
10.1.4.Firazyre
10.1.5.Berinert
10.1.6.Orladeyo
10.1.7.Cinryze
10.1.8.Haegarda
10.1.9.Takhzyro
10.1.10.Others
10.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.C1-esterase inhibitor
10.2.2.Bradykinin B2 receptor antagonist
10.2.3.Kallikrein inhibitor
10.2.4.Others
10.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Intravenous
10.3.2.Subcutaneous
10.3.3.Oral
10.3.4.Others
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Hereditary Angioedema Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Kalbitor
11.1.2.Ruconest
11.1.3.Icatibant
11.1.4.Firazyre
11.1.5.Berinert
11.1.6.Orladeyo
11.1.7.Cinryze
11.1.8.Haegarda
11.1.9.Takhzyro
11.1.10.Others
11.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.C1-esterase inhibitor
11.2.2.Bradykinin B2 receptor antagonist
11.2.3.Kallikrein inhibitor
11.2.4.Others
11.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Intravenous
11.3.2.Subcutaneous
11.3.3.Oral
11.3.4.Others
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Hereditary Angioedema Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Kalbitor
12.1.2.Ruconest
12.1.3.Icatibant
12.1.4.Firazyre
12.1.5.Berinert
12.1.6.Orladeyo
12.1.7.Cinryze
12.1.8.Haegarda
12.1.9.Takhzyro
12.1.10.Others
12.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.C1-esterase inhibitor
12.2.2.Bradykinin B2 receptor antagonist
12.2.3.Kallikrein inhibitor
12.2.4.Others
12.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Intravenous
12.3.2.Subcutaneous
12.3.3.Oral
12.3.4.Others
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Hereditary Angioedema Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Kalbitor
13.1.2.Ruconest
13.1.3.Icatibant
13.1.4.Firazyre
13.1.5.Berinert
13.1.6.Orladeyo
13.1.7.Cinryze
13.1.8.Haegarda
13.1.9.Takhzyro
13.1.10.Others
13.2.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.C1-esterase inhibitor
13.2.2.Bradykinin B2 receptor antagonist
13.2.3.Kallikrein inhibitor
13.2.4.Others
13.3.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Intravenous
13.3.2.Subcutaneous
13.3.3.Oral
13.3.4.Others
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.CSL Behring (Garadacimab)
14.2.2.Takeda
14.2.3.Pharming
14.2.4.Biocryst Pharmaceutics (BCX-4161)
14.2.5.Pharvaris (PHA 121)
14.2.6.Ionis Pharmaceuticals (Donidalorsen)
14.2.7.Attune Pharmaceuticals (ATN-249)
14.2.8.Arrowhead Pharmaceuticals (ARO-F12)
14.2.9.Adverum Biotechnologies
14.2.10.KalVista Pharmaceuticals (KVD-900, KVD 824 & Factor XIIa inhibitors)
14.2.11.Centogene
14.2.12.Spark Therapeutics (Gene Therapy)
15. Research Methodology 
16. Appendix and Abbreviations 
  • CSL Behring (Garadacimab)
  • Takeda
  • Pharming
  • Biocryst Pharmaceutics (BCX-4161)
  • Pharvaris (PHA 121)
  • Ionis Pharmaceuticals (Donidalorsen)
  • Attune Pharmaceuticals (ATN-249)
  • Arrowhead Pharmaceuticals (ARO-F12)
  • Adverum Biotechnologies
  • KalVista Pharmaceuticals (KVD-900, KVD 824 & Factor XIIa inhibitors)
  • Centogene
  • Spark Therapeutics (Gene Therapy)
  • Intellia Therapeutics (NTLA-2002)
  • Astria Therapeutics (STAR 0215)
  • ADARx Pharmaceuticals (ADX-324)
  • BioMarin Pharmaceutical (BMN-331)
  • Isis Pharmaceuticals (IONIS PKKRx)

Adjacent Markets